RWDD4A Activators
RWDD4A activators represent a range of chemical compounds that are known to engage distinct intracellular signaling mechanisms, resulting in the enhancement of RWDD4A's functional activity. Compounds such as Forskolin, Sildenafil, and Rolipram work by increasing intracellular levels of cyclic nucleotides (cAMP or cGMP), which in turn activate protein kinases A (PKA) and G (PKG). These kinases may phosphorylate substrates or alter signaling cascades that promote the activation of RWDD4A, assuming that RWDD4A is a component or regulator within these pathways. Lithium chloride and GSK-3 Inhibitor IX, as inhibitors of GSK-3, and Phorbol 12-myristate 13-acetate (PMA), an activator of PKC, are believed to modify protein-protein interactions or phosphorylation states that are directly connected to RWDD4A's role in cellular signaling, thereby enhancing its activity.
The action of Ionomycin, which raises intracellular calcium levels, possibly leading to the activation of calcium-dependent kinases that could phosphorylate RWDD4A or modulate its activity, also demonstrates the indirect activation mechanisms of RWDD4A. Similarly, Isoproterenol, through beta-adrenergic receptors, increases cAMP production, which could lead to PKA activation and subsequent enhancement of RWDD4A activity. BAY 60-6583, by inhibiting PDE2, and Zaprinast, via PDE5 and PDE9 inhibition, increase the levels of cAMP and cGMP, potentially activating PKA or PKG and thus enhancing RWDD4A activity. Additionally, Anisomycin acts as an activator of the JNK pathway, which could enhance RWDD4A through modulation of JNK-mediated signaling processes. Collectively, these activators work through their respective pathways to elevate the functional activity of RWDD4A without directly altering its expression levels.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing intracellular cAMP levels, which in turn can activate PKA. PKA phosphorylation can enhance RWDD4A activity by promoting its protein-protein interactions involved in signaling pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits PDE4, leading to increased cAMP levels, which may indirectly enhance RWDD4A activity by activating PKA-dependent signaling pathways where RWDD4A could be a downstream effector. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits GSK-3, a kinase involved in numerous signaling pathways. Inhibition of GSK-3 can lead to the activation of signaling cascades that potentially enhance the activity of RWDD4A by altering protein interactions. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, raising intracellular calcium levels and activating calcium-dependent protein kinases, which may enhance RWDD4A activity by modifying its protein-protein interaction network. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Bromoadenosine 3',5'-cyclic monophosphate is a cell-permeable cAMP analog that activates PKA. Activation of PKA can lead to phosphorylation events that might enhance RWDD4A activity through modification of its interaction with other signaling proteins. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which could lead to enhanced RWDD4A activity by promoting phosphorylation and the consequent alteration in protein-protein interactions within RWDD4A-related pathways. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that increases cAMP production, potentially enhancing RWDD4A activity by activating PKA and influencing downstream signaling proteins that interact with RWDD4A. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits PDE5 and PDE9, increasing cGMP levels, which may indirectly enhance RWDD4A activity through activation of PKG and subsequent signaling pathways. | ||||||
BAY 60-6583 | 910487-58-0 | sc-503262 | 10 mg | $210.00 | ||
BAY 60-7550 is a PDE2 inhibitor, which leads to increased cAMP and cGMP levels, potentially enhancing signaling pathways that indirectly activate RWDD4A through PKA or PKG phosphorylation cascades. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
GSK-3 Inhibitor IX is a GSK-3 inhibitor, which might indirectly enhance RWDD4A activity by modulating the signaling pathways involving GSK-3, potentially affecting the protein-protein interaction landscape of RWDD4A. | ||||||